Showing results (881-890 of 1,231) with videos related to

Sort By:
Pageof 124
Blood|January 24, 2016
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myelomaSonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, et al.
Leukemia|August 1, 2020
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Kidney International Reports|January 16, 2026
Exome-Wide Analysis Identifies a Rare <i>EXD3</i> Missense Variant Associated With Diabetic Kidney DiseaseNiina Sandholm, Joanne B Cole, Viji Nair, et al.
Haematologica|September 18, 2025
Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/refractory acute myeloid leukemiaKathelijn Verdeyen, Tom Reuvekamp, Walter J F M Van der Velden, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2024
Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trialM R Seefat, C A M Stege, B I Lissenberg-Witte, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2023
Clinical Impact of Polymerase Chain Reaction-Based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter StudySammy Huygens, Albert Dunbar, Jochem B Buil, et al.
Plos One|December 21, 2018
Correction: A 32 kb Critical Region Excluding Y402H in CFH Mediates Risk for Age-Related Macular DegenerationTheru A Sivakumaran, Robert P Igo, Jeffrey M Kidd, et al.
Diabetes|September 28, 2017
Genetically Determined Plasma Lipid Levels and Risk of Diabetic Retinopathy: A Mendelian Randomization StudyLucia Sobrin, Yong He Chong, Qiao Fan, et al.
Plos One|October 25, 2011
A 32 kb critical region excluding Y402H in CFH mediates risk for age-related macular degenerationTheru A Sivakumaran, Robert P Igo, Jeffrey M Kidd, et al.
The Lancet. Oncology|June 18, 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
Pageof 124